论文部分内容阅读
英卡胺(Encainide)是一种抑制室性异位搏动的新型抗心律失常药.早期动物实验的电生理研究显示,该药能降低自律性,减少心肌动作电位的上升速度和时限,同时延长动作电位的有效不应期.以后的研究又显示,它能有效地抑制不同种类的房性和室性心律失常.本文旨在利用动态心电图监测,运动试验和电生理试验来进一步确定英卡胺治疗室性早搏的效用.方法:21例有频发室性心律失常(48小时内室性早搏的平均数≥60次/小时)3个月以上的患者,其中男19例,女2例,平均年龄55±12岁(范围
Encainide is a new anti-arrhythmic drug that inhibits ventricular ectopic beating.Electrophysiology studies in early animal experiments show that the drug can reduce self-discipline, reduce the rate and duration of myocardial action potentials, and prolong The effective refractory period of action potential.After the study also showed that it can effectively inhibit different types of atrial and ventricular arrhythmias.This paper aims to use the dynamic electrocardiogram monitoring, exercise tests and electrophysiological tests to further determine the acetylamine treatment Ventricular premature beats.Methods: Twenty-one patients with frequent ventricular arrhythmias (average ≥60 beats per hour within 48 hours) were over 3 months, including 19 males and 2 females, with an average of Age 55 ± 12 years (range